Paradigm Capital Management Inc. NY Sells 301,600 Shares of Standard BioTools Inc. (NASDAQ:LAB)

Paradigm Capital Management Inc. NY reduced its holdings in Standard BioTools Inc. (NASDAQ:LAB - Free Report) by 54.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 248,400 shares of the company's stock after selling 301,600 shares during the quarter. Paradigm Capital Management Inc. NY owned approximately 0.07% of Standard BioTools worth $435,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of LAB. Takeda Pharmaceutical Co. Ltd. bought a new stake in Standard BioTools in the fourth quarter valued at approximately $29,000. Two Sigma Securities LLC acquired a new position in shares of Standard BioTools in the 4th quarter worth approximately $30,000. Aquatic Capital Management LLC bought a new stake in shares of Standard BioTools in the 4th quarter valued at $45,000. Cibc World Markets Corp bought a new stake in shares of Standard BioTools in the 4th quarter valued at $48,000. Finally, Simon Quick Advisors LLC bought a new position in Standard BioTools during the fourth quarter worth $54,000. Institutional investors own 53.74% of the company's stock.

Standard BioTools Trading Down 3.4%

NASDAQ LAB traded down $0.03 during trading hours on Friday, hitting $0.92. 2,591,697 shares of the company's stock were exchanged, compared to its average volume of 2,139,443. The firm has a market cap of $350.04 million, a price-to-earnings ratio of -1.30 and a beta of 1.80. The stock has a 50-day simple moving average of $1.12 and a 200 day simple moving average of $1.45. Standard BioTools Inc. has a 1-year low of $0.92 and a 1-year high of $2.65.

Insiders Place Their Bets

In related news, Director Casdin Partners Master Fund, L purchased 4,820,959 shares of the firm's stock in a transaction on Friday, February 28th. The stock was purchased at an average cost of $1.06 per share, with a total value of $5,110,216.54. Following the completion of the purchase, the director now owns 58,846,780 shares in the company, valued at approximately $62,377,586.80. This trade represents a 8.92% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders have sold 31,500 shares of company stock worth $32,069. Corporate insiders own 23.16% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, KeyCorp downgraded Standard BioTools from an "overweight" rating to a "sector weight" rating in a report on Thursday, February 27th.

Standard BioTools Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.